Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(2):118-120,124
DOI: 10.5428/pcar20190210
Practice and analysis of drug treatment for a patient with epilepsy secondary to brain metastasis from lung cancer
1. FANG Yan1(1.Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China fy40393@rjh.com.cn)
2. XU Wenyun1(1.Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China )
3. YANG Wanhua1(1.Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China )
4. JIN Zhiping2( 2.Department of Pharmacy,Zhongshan Hospital Affiliated to Fudan University,Shanghai 200032,China )
ABSTRACT  Objective: To investigate the choice of drugs for the treatment of a patient with epilepsy secondary to brain metastasis from lung cancer in the course of targeted and antiepileptic therapy. Methods: A retrospective analysis was made by using the clinical medical data of a patient with epilepsy secondary to brain metastasis from lung cancer. Results: Clinical pharmacists recommended that the targeted anti-cancer drug used for the treatment of the patient with epidermal growth factor receptor (EGFR) mutation and epilepsy secondary to brain metastasis from lung cancer be replaced with osimertinib. Aiming at the treatment of epilepsy secondary to brain metastasis from lung cancer,clinical pharmacists suggested that carbamazepine which might have potential interaction with osimertinib be abandoned,and valproate sodium,a non-enzyme-inducing activity antiepileptic drug,be used instead. Based on the detection results of therapeutic drug monitoring (TDM),the dosage of valproate sodium was timely adjusted. As a result,clinical medication safety and efficacy were ensured. Conclusion: Active involvement of pharmacists in proper adjustment of regimens in the treatment of the patient with epilepsy secondary to brain metastasis from lung cancer could ensure safe and rational use of drugs.
Welcome to PCAR! You are the number 46 reader of this article!
Please cite this article as:
FANG Yan1,XU Wenyun1,YANG Wanhua1,JIN Zhiping2,. Practice and analysis of drug treatment for a patient with epilepsy secondary to brain metastasis from lung cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 118-120,124.
References:
1. WANG Yu,LIU Ruming,XU Yingying, et al. EGFR-TKI combined with WBRT for NSCLC complicated with brain metastasis:A Meta-analysis[J]. China Pharmacy,2014,25(28): 2651-2655. In Chinese with English abstract.
2. Sasada T,Yamada T,Azuma K,et al. EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer[J]. J Immunother Cancer, 2013,1(Suppl 1): P235.
3. HE Lu,QIAN Yan. Research progress of osimertinib in treating non-small cell lung cancer[J].Chin J New Drugs Clin Rem,2016,35(6):398-404.In Chinese with English abstract.
4. AstraZeneca Pharmaceuticals LP. Full prescribing information for TAGRISSO (osimertinib) tablets[EB/OL].[2018-04-02]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf.
5. Remon J,Planchard D. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients[J]. Future Oncol,2015,11(22): 3069-3081.
6. SHI Yuankai,SUN Yan,YU Jinming,et al. China experts consensus on the diagnosis and treatment of brain metastases of lung cancer (2017 version) [J]. Chin J Lung Cancer,2017,20(1): 1-12. In Chinese with English title.
7. Kivist K T,Kroemer H K,Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions[J]. Br J Clin Pharmacol,1995,40(6): 523-530.
8. Khozin S,Weinstock C,Blumenthal G M,et al. Osimertinib for the treatment of metastatic EGFR T970M mutation-positive non-small cell lung cancer[J]. Clin Cancer Res,2016,23(9):2131-2135.
9. Dickinson P A,Cantarini M V,Collier J,et al. Metabolic disposition of osimertinib in rat,dog,and man: insights into a drug designed to bind covalently to a cysteine residue of EGFR[J]. Drug Metab Dispos,2016,44(8): 1201-1212.
10. MIAO Xiusheng,YANG Jianjun,Metcalfe C D. Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant[J]. Environ Sci Technol,2005,39(19): 7469-7475.
11. Greig S L. Osimertinib: first global approval[J]. Drugs,2016,76(2): 263-273.
12. van Breemen M S,Wilms E B,Vecht C J. Epilepsy in patients with brain tumours: epidemiology,mechanisms,and management[J]. Lancet Neurol,2007,6(5): 421-430.
13. van Breemen M S,Rijsman R M,Taphoorn M J,et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures[J]. J Neurol,2009,256(9): 1519-1526.
14. BAN Lili,TANG Xiaoxia. Association of blood concentration of sodium valproate with anti-epileptic efficacy and adverse drug reactions[J]. Eval Anal Drug-use Hosp China,2013,13(12):1086-1089. In Chinese with English abstract.
15. WANG Honghong,MAO Guifu,TAN Qiang. The research overview on blood concentration monitoring of sodium velproate[J]. Qilu Pharm Aff,2012,31(10): 605-607. In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口